`Filed: July 6, 2018
`
`Filed on behalf of: Mylan Pharmaceuticals Inc.
`By: Steven W. Parmelee
`
`Michael T. Rosato
`
`Jad A. Mills
`WILSON SONSINI GOODRICH & ROSATI
`
`701 Fifth Avenue, Suite 5100
`Seattle, WA 98104-7036
`
`
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`_____________________________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`_____________________________
`
`MYLAN PHARMACEUTICALS INC.,
`Petitioner,
`
`v.
`
`ANACOR PHARMACEUTICALS, INC.,
`Patent Owner.
`
`_____________________________
`Case IPR2018-01358
`Patent 9,549,938
`
`
`MOTION FOR JOINDER UNDER 35 U.S.C. § 315(c)
`AND 37 C.F.R. §§42.22 AND 42.122(b)
`
`
`
`
`
`
`
`
`
`
`
`I.
`
`Statement of the Precise Relief Requested
`
`Mylan Pharmaceuticals Inc. (“Mylan” or “Petitioner”) submits, concurrently
`
`with this motion, a petition for inter partes review (“Petition”) of claims 1-6 of
`
`U.S. Patent No. 9,549,938 (“the ’938 patent”), which is assigned to Anacor
`
`Pharmaceuticals, Inc. (“Patent Owner”). Mylan respectfully requests joinder
`
`pursuant to 35 U.S.C. § 315(c) and 37 C.F.R. § 42.122(b) of the concurrently filed
`
`Petition with a pending inter partes review initiated by FlatWing Pharmaceuticals
`
`LLC (“FlatWing”), IPR2018-00168. Petitioner requests joinder as to the instituted
`
`grounds, Grounds 1-4.
`
`Joinder will promote efficiency and consistent resolution of substantively
`
`identical challenges to the same patent. This motion for joinder is timely because it
`
`is filed within one month of the institution decision in IPR2018-00168. Joinder
`
`should create no unfair burden for the Board, Patent Owner, or FlatWing because
`
`these grounds are substantive copies of grounds from the original petition filed in
`
`IPR2018-00168, which Grounds have all been instituted. The present Petition
`
`contains only minor modifications from the petition in IPR2018-00168, such as
`
`changes to address the identity of the petitioner, the request for joinder with
`
`IPR2018-00168, and formatting the Identification of the Challenge as a chart. The
`
`Petition relies upon the expert declaration of Dr. Stephen Kahl, Ph.D (Ex. 1003)
`
`and the expert declaration of Dr. S. Narasimha Murthy, Ph.D (Ex. 1005), each of
`
`-1-
`
`
`
`which was submitted in IPR2018-00168. Petitioner has updated the exhibit
`
`labeling to match the case information for this case.
`
`Absent termination of FlatWing as a party to the proceeding, Mylan
`
`anticipates participating in a joined proceeding in an understudy role. Moreover,
`
`joinder will have no impact on the trial schedule of IPR2018-00168 because that
`
`IPR is still in its early trial stages, and Mylan, in its limited role, is agreeable to the
`
`same schedule. Mylan is not subject to any time-bar under 35 U.S.C. § 315. As
`
`such, Mylan requests institution of the petition even if the Board decides against
`
`joinder with IPR2018-00168.
`
`II. Background
`
`On November 21, 2017, FlatWing filed a petition for inter partes review
`
`challenging claims 1-6 of the ’938 patent, Case No. IPR2018-00168. On June 8,
`
`2018, the Board instituted review on claims 1-6. This Petition is a practical copy of
`
`the IPR2018-00168 petition, including the same prior art analysis and identical
`
`expert testimony. See Pet.
`
`III. Argument
`
`A. Legal Standard
`
`The Board has authority to join as a party any person who properly files a
`
`petition for inter partes review to an instituted inter partes review. 35 U.S.C.
`
`§315(c). A motion for joinder must be filed within one month of institution of any
`
`inter partes review for which joinder is requested. 37 C.F.R. § 42.122(b). In
`-2-
`
`
`
`
`
`deciding whether to grant a motion for joinder, the Board considers several factors
`
`including: (1) the reasons why joinder is appropriate; (2) whether the party to be
`
`joined has presented any new grounds of unpatentability; (3) what impact, if any,
`
`joinder would have on the trial schedule for the existing review; and (4) how
`
`briefing and discovery may be simplified. See, e.g., Hyundai Motor Co. v. Am.
`
`Vehicular Sciences LLC, IPR2014-01543, Paper No. 11 at 3 (Oct. 24, 2014);
`
`Macronix Int’l Co. v. Spansion, IPR2014-00898, Paper 15 at 4 (Aug. 13, 2014)
`
`(quoting Kyocera Corporation v. Softview LLC, IPR2013-00004, Paper 15 at 4
`
`(April 24, 2013)).
`
`B. Mylan’s Motion for Joinder Is Timely
`
`Joinder may be requested no later than one month after the institution date of
`
`an inter partes review for which joinder is requested. 37 C.F.R. § 42.122. Here,
`
`because the Board issued its institution decision in IPR2018-00168 on June 8,
`
`2018, this Motion for Joinder and the accompanying Petition are timely.
`
`C. The Relevant Factors Weigh in Favor of Joinder
`
`Each of the four factors considered by the Board weighs in favor of joinder.
`
`As discussed below, granting joinder will not enlarge the scope of the IPR2018-
`
`00168 beyond that proposed in the original petition and will not negatively impact
`
`the IPR2018-00168 schedule.
`
`
`
`-3-
`
`
`
`1.
`
`Joinder is Appropriate
`
`Joinder with IPR2018-00168 is appropriate because the Petition is limited to
`
`the same grounds proposed in the IPR2018-00168 petition, all of which were
`
`instituted. It also relies on the same prior art analysis and identical expert
`
`testimony to that submitted by FlatWing. Indeed, the Petition is nearly identical
`
`with respect to the grounds raised in the IPR2018-00168 petition, and does not
`
`include any grounds not raised in that petition.
`
`Joinder is also appropriate because it will promote the just, speedy, and
`
`inexpensive resolution of patentability issues, including the determination of
`
`patentability of the challenged claims of the ’938 patent. Mylan is not time-barred
`
`under 35 U.S.C. § 315, so joinder will obviate the need to burden the Board with
`
`two separate IPR trials based on identical grounds and evidence.
`
`Moreover, granting joinder will not prejudice Patent Owner or FlatWing. As
`
`mentioned above, the accompanying Petition does not raise any new ground that is
`
`not raised in the IPR2018-00168 petition. Therefore, joinder should not
`
`significantly affect the timing in IPR2018-00168. Also, there should be little to no
`
`additional cost to Patent Owner or FlatWing given the absence of new grounds. On
`
`the other hand, Mylan and the public may be potentially prejudiced if joinder is
`
`denied. For example, absent joinder, Patent Owner and FlatWing might settle and
`
`
`
`-4-
`
`
`
`request termination of the proceedings, leaving facially intact a patent that the
`
`Board has already found is likely unpatentable.
`
`2.
`
`No New Grounds Are Presented
`
`The Petition does not present any new ground of unpatentability. As
`
`mentioned above, the Petition presents for review substantively identical grounds
`
`from the petition in IPR2018-00168 that have been instituted. The present Petition
`
`is based on the same prior art analysis and expert testimony that was submitted by
`
`FlatWing. The Board has granted joinder where doing so does not introduce any
`
`additional arguments. See, e.g., Hyundai, IPR2014-01543, Paper No. 11 at 2-4;
`
`Sony Corp. of Am. v. Network-1 Sec. Solutions, Inc., IPR2013-00495, Paper No. 13
`
`at 5-9 (Sep. 16, 2013); Dell Inc. v. Network-1 Solutions, Inc., IPR2013-00385,
`
`Paper No. 17, at 6-10 (Jul. 29, 2013); Motorola Mobility LLC v. Softview LLC,
`
`IPR2013-00256, Paper 10 at 4-10 (June 20, 2013).
`
`3.
`
`Joinder Will Not Negatively Impact the IPR2018-00168
`Trial Schedule
`
`Because the Petition essentially copies grounds raised in the IPR2018-00168
`
`petition, including the prior art analysis and expert testimony substantively
`
`identical to that provided by FlatWing, joinder will have no substantial effect on
`
`the parties, or prevent the Board from issuing a final written decision in a timely
`
`manner. The timing and content of Mylan’s petition and motion for joinder
`
`minimize any impact to the IPR2018-00168 trial schedule. Moreover, as discussed
`
`
`
`-5-
`
`
`
`above, Mylan anticipates participating in the proceeding in a limited capacity as an
`
`understudy, absent termination of FlatWing as a party. For example, if the
`
`proceedings are joined and absent termination of FlatWing, it is anticipated that no
`
`expert witnesses beyond those presented by FlatWing and Patent Owner will
`
`present testimony. Accordingly, Mylan does not believe that any extension of the
`
`schedule will be required by virtue of joinder of Mylan as a petitioner to this
`
`proceeding.
`
`4.
`
`Discovery and Briefing Can Be Simplified
`
`Given the Petition is identical to the IPR2018-00168 petition with respect to
`
`grounds of unpatentability raised, the Board may adopt procedures similar to those
`
`used in other cases to simplify briefing and discovery during trial. See e.g.,
`
`Hyundai, IPR2014-01543, Paper No. 11 at 5; Dell, IPR2013-00385, Paper No. 17
`
`at 8-10; Motorola, IPR2013-00256, Paper 10 at 8-10. Specifically, as long as
`
`FlatWing remains a party, the Board may order petitioners to consolidate filings,
`
`and to limit Mylan to no additional filings in its understudy role. As long as
`
`FlatWing remains a party, Mylan will not submit any separate filings unless it
`
`disagrees with FlatWing’s position (which it is not anticipated), and in the event of
`
`such disagreement it will request authorization from the Board to submit a short
`
`separate filing directed only to points of disagreement with FlatWing. The Board
`
`
`
`-6-
`
`
`
`may allow the Patent Owner a corresponding number of pages to respond to any
`
`separate filings. See Dell Inc., supra, at 8-9.
`
`Further, so long as FlatWing remains a party to IPR2018-00168, no
`
`additional depositions will be needed and depositions will be completed within
`
`ordinary time limits. Additionally, Mylan will not seek to rely on separate expert
`
`testimony than that submitted by FlatWing except to the extent that Mylan may be
`
`precluded from relying on FlatWing’s experts, e.g., if FlatWing settles with patent
`
`owner and contractually precludes its experts from continuing in the IPR with
`
`Mylan.
`
`Moreover, to the extent that Mylan is permitted to participate in the
`
`proceedings, Mylan will endeavor to coordinate with FlatWing to consolidate
`
`authorized filings, manage questioning at depositions, ensure that briefing and
`
`discovery occur within the time normally allotted, and avoid redundancies. Mylan
`
`will maintain a secondary role in the joined proceeding, and will assume a primary
`
`role only if FlatWing ceases to participate in the IPR. As noted above, Mylan is
`
`willing to take a backseat role, in which it would not file any separate papers
`
`without consultation with FlatWing and prior authorization from the Board. These
`
`procedures should simplify briefing and discovery and remove any “complication
`
`or delay” that might allegedly be caused by joinder, while providing the parties an
`
`
`
`-7-
`
`
`
`opportunity to address all issues that may arise, and avoiding any undue burden on
`
`Patent Owner, FlatWing, and the Board.
`
`IV. Conclusion
`
`For the foregoing reasons, Mylan respectfully requests that this motion be
`
`granted and an inter partes review of the challenged claims 1-6 be instituted based
`
`on the grounds 1-4, and that this proceeding be joined with IPR2018-00168.
`
`Dated: July 6, 2018
`
`Respectfully submitted,
`
`/ Steven W. Parmelee /
`Steven W. Parmelee, Lead Counsel
`Reg. No. 31,990
`
`
`
`
`
`
`
`-8-
`
`
`
`CERTIFICATE OF SERVICE
`
`Pursuant to 37 C.F.R. §§ 42.6(e) and 42.105(a), this is to certify that I
`
`caused to be served a true and correct copy of the foregoing Motion for Joinder by
`
`overnight courier (Federal Express or UPS), on this 6th day of July, 2018, on the
`
`Patent Owner at the correspondence address of the Patent Owner as follows:
`
`MORGAN, LEWIS & BOCKIUS LLP (SF)
`Attn: Todd Esker
`One Market, Spear Street Tower, Suite 2800
`San Francisco CA 94105
`
`
`and that additional copies have been delivered to the address of the patent
`
`owner according to the assignments of record at the USPTO at:
`
`ANACOR PHARMACEUTICALS, INC.
`Attn: Ryan Walsh, Vice-President & Chief IP counsel
`1020 East Meadow Circle
`Palo Alto, CA 94303
`
`and to additional counsel at the following address:
`
`Williams & Connoly LLP
`Attn: Aaron Maurer and David Berl
`725 Twelfth Street, N.W.
`Washington, DC 20005
`
`
`
`
`
`-9-
`
`
`
`And to counsel for Petitioner FlatWing Pharmaceuticals LLC in IPR2018-
`
`00168, as follows:
`
`Husch Blackwell, LLP
`Attn: Philip D. Segrest, Jr.
`120 South Riverside Plaza
`Suite 2200
`Chicago, IL 60606
`
`
`
`
`
`
`
`
`
`Respectfully submitted,
`
`/ Steven W. Parmelee /
`Steven W. Parmelee, Lead Counsel
`Reg. No. 31,990
`
`
`
`Dated: July 6, 2016
`
`
`
`
`
`-10-
`
`